Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Zahi Merjaneh"'
Publikováno v:
Translational Oncology, Vol 14, Iss 9, Pp 101156- (2021)
Externí odkaz:
https://doaj.org/article/77c73c23848e43e3b6be5ae7f9074912
Autor:
Jame Abraham, Amal Farouk, Mohamed M. Gad, Anas M. Saad, Firas Baidoun, Khalid A. Jazieh, Zahi Merjaneh, Nataly Valeria Torrejon, Moshe Chaim Ornstein
Publikováno v:
Breast Cancer Research and Treatment. 191:643-652
Purpose: There are case reports of patients with both primary breast cancer (BC) and renal cell carcinoma (RCC). We explore the association between these two malignancies using SEER population data and our institutional records.Methods: We studied th
Autor:
Kholoud Elshiwy, Muneer J. Al-Husseini, Muhammad Talal Sarmini, Zahi Merjaneh, George Khoudari, Yasmine Elkeraie, Firas Baidoun, Mohamed M. Gad, Anas M. Saad
Publikováno v:
Current Drug Targets. 22:998-1009
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer related deaths in the world with an estimated number of 1.8 million new cases and about 881,000 deaths worldwide in 2018. The epidemiology of CRC varies si
Publikováno v:
Journal of comparative effectiveness research. 11(13)
IntroductionWhile surgical resection for primary tumor and distant metastases is recommended among individuals with resectable colorectal liver metastases, the role and timing of perioperative systemic therapy is not yet defined.Materials and Methods
Publikováno v:
European journal of gastroenterologyhepatology. 34(3)
Cholangiocarcinoma is a rare malignancy accounting for 3% of gastrointestinal cancers in the USA. While multiple risk factors for cholangiocarcinoma are established, other potential risk factors are still controversial. Herein, we used a large nation
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 9, Pp 101156-(2021)
Translational Oncology, Vol 14, Iss 9, Pp 101156-(2021)
Publikováno v:
Annals of Oncology. 32:S211
Publikováno v:
Gastroenterology. 156:S-401
Autor:
Vijay A. Reddy, Tomasz Pielak, Laurence S. Sperling, Ravi Nanjundappa, Stamatios Lerakis, Ayman Samman Tahhan, Riyaz S. Patel, Danny J. Eapen, Kiran Valiani, Maan Malahfji, Zahi Merjaneh, Mohamed Khayata, Christian W. Thorball, Hatem Al Kassem, Nima Ghasemzadeh, Arshed A. Quyyumi, Pankaj Manocha, Ibhar Al Mheid
Publikováno v:
Journal of the American College of Cardiology. 61(10)
Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of systemic inflammation. Recent studies have associated suPAR with presence and severity of coronary artery disease (CAD). However, the prognostic implication of suPAR in patien